secwatch.observer — SEC 8-K summary
======================================

Issuer:     AYTU BIOPHARMA, INC (AYTU)
CIK:        0001385818
Form:       8-K
Filed at:   2024-11-13T23:59:59+00:00
Accession:  0001437749-24-034898
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 5.02, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aytu BioPharma Q1 net income $1.5M; promotes Ryan Selhorn as CFO
----------------------------------------------------------------

- Net income of $1.5M vs net loss of $8.1M YoY; diluted EPS $0.15 loss vs $1.48 loss.
- Adjusted EBITDA $1.9M, down 21% from $2.4M; cash stable at $20.1M.
- ADHD Portfolio net revenue $15.3M (+1% YoY); Pediatric Portfolio up 54% sequentially.
- CFO Mark Oki terminated; Ryan Selhorn appointed CFO with base salary $400K.
- Board separated Chairman/CEO roles; John Donofrio appointed Chairman.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1385818/000143774924034898/0001437749-24-034898-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1385818/000143774924034898/aytu20240909_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-24-034898

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer